Insiders At Rocket Pharmaceuticals Sold US$2.0m In Stock, Alluding To Potential Weakness
Insiders At Rocket Pharmaceuticals Sold US$2.0m In Stock, Alluding To Potential Weakness
The fact that multiple Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.
在過去的一年中，多位火箭製藥公司（納斯達克股票代碼：RCKT）內部人士拋售了大量股票，這一事實可能會引起投資者的關注。在分析內幕交易時，了解內部人士是否在買入通常比知道他們是否在賣出更有價值，因爲後者發出的信息模棱兩可。但是，股東應更深入地研究是否有幾位內部人士在特定時間段內出售股票。
Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.
儘管我們認爲股東不應該簡單地關注內幕交易，但邏輯要求你應該注意內部人士是在買入還是賣出股票。
The Last 12 Months Of Insider Transactions At Rocket Pharmaceuticals
Rocket Pharmicals最近12個月的內幕交易
The CEO & Director, Gaurav Shah, made the biggest insider sale in the last 12 months. That single transaction was for US$605k worth of shares at a price of US$29.84 each. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The good news is that this large sale was at well above current price of US$21.98. So it is hard to draw any strong conclusion from it.
首席執行官兼董事高拉夫·沙阿進行了過去12個月中最大規模的內幕出售。這筆單筆交易是價值60.5萬美元的股票，每股價格爲29.84美元。儘管內幕拋售是負面的，但對我們來說，如果以較低的價格出售股票，則負面影響更大。好消息是，此次大宗銷售遠高於當前的21.98美元。因此，很難從中得出任何有力的結論。
In the last year Rocket Pharmaceuticals insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
去年，火箭製藥內部人士沒有購買任何公司股票。你可以在下面看到過去 12 個月內幕交易（公司和個人）的直觀描述。通過點擊下面的圖表，你可以看到每筆內幕交易的確切細節！
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).
如果你喜歡買內部人士買入而不是賣出的股票，那麼你可能會喜歡這份免費的公司名單。（提示：業內人士一直在購買它們）。
Insiders At Rocket Pharmaceuticals Have Sold Stock Recently
Rocket Pharmicals的內部人士最近出售
The last three months saw significant insider selling at Rocket Pharmaceuticals. In total, insiders dumped US$1.8m worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain.
在過去的三個月中，Rocket Pharmicals出現了大量的內幕銷售。在此期間，內部人士總共拋售了價值180萬美元的股票，我們沒有記錄任何購買記錄。有鑑於此，很難說所有內部人士都認爲股票很划算。
Insider Ownership
內部所有權
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Rocket Pharmaceuticals insiders own about US$51m worth of shares. That equates to 2.5% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
查看公司的內部持股總量可以幫助你了解他們是否與普通股股東保持一致。我們通常希望看到相當高的內部所有權水平。火箭製藥內部人士擁有價值約5100萬美元的股票。這相當於該公司的2.5％。儘管這是一個強勁但並不突出的內部所有權水平，但這足以表明管理層與小型股東之間有一定的一致性。
What Might The Insider Transactions At Rocket Pharmaceuticals Tell Us?
Rocket Pharmaceuticals的內幕交易可能告訴我們什麼？
Insiders sold Rocket Pharmaceuticals shares recently, but they didn't buy any. Looking to the last twelve months, our data doesn't show any insider buying. Insiders own shares, but we're still pretty cautious, given the history of sales. We're in no rush to buy! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Rocket Pharmaceuticals. For example, Rocket Pharmaceuticals has 4 warning signs (and 1 which is potentially serious) we think you should know about.
業內人士最近出售了火箭製藥的股票，但他們沒有買入任何股票。展望過去的十二個月，我們的數據並未顯示任何內幕買盤。內部人士擁有股票，但考慮到銷售歷史，我們仍然相當謹慎。我們並不急於購買！除了了解正在進行的內幕交易外，確定Rocket Pharmicals面臨的風險也是有益的。例如，Rocket Pharmaceuticals有4個警告信號（其中一個可能很嚴重），我們認爲你應該知道。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果你想看看另一家公司——一家財務狀況可能優越的公司——那麼千萬不要錯過這份免費的股本回報率高、債務低的有趣公司的名單。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言，內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益，不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎？對內容感到擔憂？直接聯繫我們。 或者，給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論，我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議，也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意，我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之，華爾街沒有持有任何上述股票的頭寸。
譯文內容由第三人軟體翻譯。